On 4 July 2025, the EC fined Alchem and its subsidiary EUR 489,000 for their role in a long-running cartel concerning the active pharmaceutical ingredient SNBB, used in the production of Buscopan and its generics. This marks...more
7/23/2025
/ Antitrust Violations ,
Cartels ,
Competition ,
Drug Pricing ,
Enforcement Actions ,
EU ,
European Commission ,
Healthcare ,
Life Sciences ,
Penalties ,
Pharmaceutical Industry ,
Prescription Drugs
2024 saw a significant increase in overall global fines for antitrust enforcement, with total penalties for the jurisdictions surveyed in our report at USD6.7 billion, over double that of 2023 (USD2.9bn) and substantially...more
3/19/2025
/ Abuse of Dominance ,
Antitrust Provisions ,
Antitrust Violations ,
Artificial Intelligence ,
Asia Pacific ,
Big Tech ,
Cartels ,
Competition ,
Damages ,
Digital Assets ,
Digital Markets Strategy ,
Dispute Resolution ,
Enforcement Actions ,
EU ,
European Commission ,
Fines ,
Regulatory Agenda ,
Regulatory Reform ,
Regulatory Requirements ,
South Africa ,
Sustainability ,
Technology Sector ,
UK ,
United States
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active pharmaceutical ingredient (API)...more
10/23/2023
/ Cartels ,
Cephalon ,
Competition ,
Corporate Counsel ,
EU ,
European Commission ,
Generic Drugs ,
Life Sciences ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Teva Pharmaceuticals